FF-10832 Granted FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
The FDA grants orphan drug designation to support the development of therapies for rare diseases that affect fewer than 200,000 people in the U.S.1 Small patient populations can limit preclinical research and slow clinical trials, stalling progress in therapeutic development for rare diseases. The designation supports research and clinical development by providing 7-years marketing exclusivity and other financial incentives.
There are approximately 16,000 new cases of BTC in the U.S per year.2 Most (≥70%) patients present with unresectable or metastatic disease at diagnosis, and current treatments of surgery, chemotherapy, and radiation show limited efficacy in advanced stages. High recurrence (50–70%) and low 5-year survival rates (4–13%) highlight the urgent need for new and effective treatments.
Gemcitabine has been a key component of BTC treatment since its approval in the 1990s, with all major first line regimens currently containing gemcitabine.3 FF-10832's novel liposomal formulation of gemcitabine for intravenous administration is designed to enhance anti-tumor activity by prolonging plasma half-life and improving targeted delivery to tumors.
"BTCs are rare but aggressive malignancies associated with a poor prognosis and limited treatment options," said Susumu Shimoyama, president, FUJIFILM Pharmaceuticals U.S.A., Inc. "Receiving orphan drug designation highlights the significant unmet medical need that still remains and supports development of FF-10832 for patients with BTC who have few satisfactory options."
FF-10832 is manufactured by FUJIFILM Toyama Chemical, providing seamless CDMO end-to-end services for full integration from formulation development to GMP manufacturing. Fujifilm's investigational drug candidates FF-10502 and FF-10850 have also been granted orphan drug designations for cholangiocarcinoma and Merkel cell carcinoma, respectively.
About FUJIFILM
FUJIFILM Pharmaceuticals U.S.A., Inc., based in Boston, Massachusetts, specializes in next generation drug delivery system formulation and CDMO services for precision treatment and care. In addition, the Company builds and maintains relationships with medical institutions, academic partners, and industry partners to conduct clinical trials and advance development of unique therapeutic compounds in oncology pipelines. For more information, please visit www.fujifilmpharma.com.
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.
For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.
1 Food and Drug Administration (FDA). 2013. 21CFR Part 316 - Relevant Excerpts. Available at https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts, accessed 2025 May 10.
2 Lowe RC, Anderson CD. 2024. Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma. UpToDate [website]. Available at: https://www.uptodate.com/contents/epidemiology-risk-factors-anatomy-and-pathology-of-cholangiocarcinoma?search=cholangiocarcinoma&source=search_result&selectedTitle=4%7E145&usage_type=default&display_rank=4, accessed 2025 April 29.
3 Rizzo A, Brandi G. 2021. Cancer Treat Res Commun 27:100335, PMID: 33592561.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707338743/en/
Contacts
Media Michele DarnellFUJIFILM Holdings America CorporationE-mail: michele.darnell@fujifilm.com
Megan AugustineFUJIFILM Holdings America CorporationE-mail: megan.augustine.contractor@fujifilm.com
Other Contacts FUJIFILM Pharmaceuticals U.S.A., Inc.fphucontact@fujifilm.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Genesis HealthCare Sets New Course to Strengthen Future
KENNETT SQUARE, Pa.--(BUSINESS WIRE)-- Genesis HealthCare, Inc., along with its subsidiaries, announced today that it has taken steps to implement a financial restructuring to secure the long-term delivery of its mission. This process is designed to ensure that the Company can continue operating in a seamless manner, while also allowing the Company to address its legacy liabilities associated with previously divested operations. To facilitate the Company's restructuring efficiently and with minimal disruption to ongoing operations, the Company has filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of Texas Dallas Division (the "Court"). 'We have much to be proud of for the tremendous progress we have made as an organization over the last several years as we have implemented a forward-looking, enterprise-wide shift from centralized to market-based operations,' said David Harrington, Executive Chairman of the Genesis HealthCare, Inc., Board of Directors. 'Our ongoing work has confirmed that, to maintain our momentum, we must address our legacy debt structure. The goal of this filing is to emerge a stronger, healthier company poised to exceed our goals for clinical and operational excellence.' Chapter 11 of the U.S. Bankruptcy Code guides how a company can restructure its debt while continuing to operate normally during the reorganization. Subject to Court approval, the Company has secured a commitment of $30 million in debtor-in-possession (DIP) financing, from its existing secured lenders. This DIP financing, combined with cash on hand and cash flow generated from ongoing operations, will support the business to satisfy its ongoing obligations, and enable the Company to remain focused on delivering quality care during the Court-supervised process. Importantly, the filing includes provisions to ensure that staff will retain their positions, pay and benefits so that patients and residents will continue to be served by the providers they trust. Vendor agreements will remain in place while the process moves forward. 'We believe this financial reorganization is a necessary step for our organization to sustainably deliver on our mission of improving lives through delivery of high-quality healthcare and everyday compassion,' said Lauren Murray, Genesis HealthCare Chief Operating Officer. 'We assure all those who rely on us for care that we remain fully focused on and committed to providing the high-quality care you have come to expect, and we thank you for your continued confidence. This process is designed to ensure that we can continue to deliver on that commitment. We also are grateful for our talented staff and their dedication to excellence, which has positioned Genesis HealthCare for continued growth and a bright future.' Court filings and additional information related to the proceedings, which include a proposed transaction involving a current affiliate, are available at The proposed transaction is subject to higher bidding and court approval, and would result in the current affiliate acquiring the Company's operations. Those with further questions can call (toll-free in the US) 888-861-3979. Advisors McDermott Will & Emery LLP is serving as legal counsel, Ankura Consulting is providing financial restructuring and Chief Restructuring Officer services (Russell A. Perry and Louis E. Robichaux IV, Co-CROs), and Jefferies is serving as exclusive investment banker. Genesis HealthCare, Inc. is a holding company with affiliates that operate skilled nursing facilities and assisted/senior living communities. Its subsidiaries also specialize in contract rehabilitation therapy, respiratory therapy, physician services, and accountable care, collectively referred to as Genesis HealthCare. To learn more, visit
Yahoo
2 hours ago
- Yahoo
Tesla (TSLA) Falls 6.79% on Elon Musk Spat with Trump
Tesla, Inc. (NASDAQ:TSLA) is one of the . Tesla, Inc. (NASDAQ:TSLA) tumbled by 6.79 percent on Monday to finish at $293.94 apiece and lost as much as $68 billion in market value amid concerns about Elon Musk's feud with President Donald Trump. This followed Musk's announcement that he would launch a new political party called the 'America Party' and could focus on just two or three Senate seats and eight to 10 House districts, enough 'to serve as the deciding vote on contentious laws, ensuring that they serve the true will of the people.' Trump, on the other hand, called Musk's plans 'ridiculous,' saying that he was saddened 'to watch Elon Musk go completely off the rails, essentially becoming a TRAIN WRECK over the past five weeks.' For investment firm Wedbush, Musk's planned political party is a move that would rattle investors. 'Very simply, Musk diving deeper into politics and now trying to take on the Beltway establishment is exactly the opposite direction that Tesla investors/shareholders want him to take during this crucial period for the [Tesla, Inc. (NASDAQ:TSLA)]story,' it was quoted as saying in a report by Guardian. While we acknowledge the potential of TSLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Applied Digital (APLD) Loses 7.56% on Lack of Leads
Applied Digital Corporation (NASDAQ:APLD) is one of the . Applied Digital tumbled for a second day on Monday, losing 7.56 percent to close at $9.66 apiece amid the lack of fresh catalysts to boost investing appetite while trading lower in line with the broader market. In recent news, Applied Digital Corporation (NASDAQ:APLD) entered into a $7-billion lease agreement with CoreWeave, Inc. (NASDAQ:CRWV). Under the agreement covering two 15-year leases, Applied Digital Corporation (NASDAQ:APLD) will deliver 250 megawatts of critical IT load to host CoreWeave, Inc.'s (NASDAQ:CRWV) artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North Dakota data center campus. An overhead view of a large-scale data center with rows of servers and blinking lights. It expects to deliver the first 100 MW of data center in the fourth quarter of the year, while the remaining 150 MW is expected to come online in the middle of 2026. Following the news, B. Riley gave Applied Digital Corporation (NASDAQ:APLD) a 'buy' recommendation and a new price target of $15, nearly double the $8 price target previously. While we acknowledge the potential of APLD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data